7 completed, 2 terminated. 6 Phase 1, 3 Phase 3, 1 Phase 2.
By phase and status
Follow CP-945,598: new trials by email Literature Review of CP-945,598 trials Research Report on CP-945,598
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
The Role of Endocannabinoids in Insulin Production and Action Nabilone, CP-945,598, hyperglycemic clamp - Healthy Volunteers Phase 1 Completed 45 2012-01-05 2026-10-13 Study Examining The Effect Of Hepatic Impairment On Safety, Toleration And How The Body Processes An Experimental Drug CP-945,598 - Obesity, Hepatic Insufficiency Phase 1 Completed 24 2008-04-01 2009-08-27 Study Examing The Effect Of Omeprazole On Safety, Tolerability And How The Body Processes An Experimental Drug CP-945,598 - Obesity Phase 1 Completed 28 2008-04-01 2009-08-13 A 14-Month Study On The Effects Of CP-945,598 For The Prevention Of Weight Regain In Obese Patients CP-945,598, Non-pharmacological weight loss program (NPP), Low Calorie Diet - Obesity Phase 3 Terminated 699 2008-01-01 2012-11-07 Study Examing The Effect of Grapefruit Juice On The Blood And Urine Samples of Study Drug And Its By Product And Safety CP-945,598 - Obesity Phase 1 Completed 28 2007-06-01 2009-08-10 Study Examining The Effect Of Renal Impairment On Safety, Toleration And How The Body Processes An Experimental Drug CP-945,598 - Obesity Phase 1 Completed 17 2007-06-01 2009-08-13 Effect of Diltiazem Administration on CP-945,598 Pharmacokinetics CP-945,598 - Obesity Phase 1 Completed 28 2007-03-01 2009-09-17 A 1-Year Study On The Effects Of CP-945,598 For The Treatment Of Obesity In Overweight Type 2 Diabetic Patients Placebo, CP-945,598, CP-945,598 Treatment B - Obesity Phase 3 Terminated 975 2006-11-01 2012-11-07 A Study Of 6-Month Duration To Evaluate The Weight Loss Effect Of Various Doses Of CP-945,598 In Obese Subjects CP-945,598, sibutramine - Obesity Phase 2 / Phase 3 Completed 282 2005-03-01 2009-08-12
Conditions studied Obesity (8) · Hepatic Insufficiency (1) · Insulin Resistance (1)
Sponsors Pfizer (8) · National Institute on Aging (NIA) (1)
Countries United States (9) · Australia (2) · Argentina (1) · Brazil (1) · Canada (1) · Czechia (1) · Denmark (1) · Germany (1) · Mexico (1) · Netherlands (1) · Slovakia (1) · South Africa (1) · Sweden (1) · United Kingdom (1)
Top investigators Chee W Chia, M.D. (1)